# Transthyretin Amyloid Cardiomyopathy (ATTR CM) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy-attr-cm

> 8 upcoming FDA catalysts in transthyretin Amyloid Cardiomyopathy (ATTR CM): NNC6019-0001 (NVO) on Feb to May 2028 (topline data readout); NNC6019-0001 (NVO) on February 2028 (primary completion); WAINUA (eplontersen, AZN) on Feb to May 2029 (topline data readout); WAINUA (eplontersen, AZN) on February 2029 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2028 | [NNC6019-0001 topline data readout](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT06260709 (A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260709)) |
| February 2028 | [NNC6019-0001 primary completion](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT06260709 (A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260709)) |
| Feb to May 2029 | [WAINUA (eplontersen) topline data readout](https://sec-api.dev/pdufa/eplontersen) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07608354 (A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07608354)) |
| February 2029 | [WAINUA (eplontersen) primary completion](https://sec-api.dev/pdufa/eplontersen) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07608354 (A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07608354)) |
| Jun to Sep 2029 | [NNC6019-0001 topline data readout](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT07207811 (CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07207811)) |
| June 2029 | [NNC6019-0001 primary completion](https://sec-api.dev/pdufa/nnc6019-0001) | NVO | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | scheduled | "NCT07207811 (CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07207811)) |
| Jul to Oct 2030 | [ALXN2220 topline data readout](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07789483 (An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07789483)) |
| July 2030 | [ALXN2220 primary completion](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | scheduled | "NCT07789483 (An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-11 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07789483)) |

## Drugs

- [NNC6019-0001](https://sec-api.dev/pdufa/nnc6019-0001) (NVO)
- [WAINUA (eplontersen)](https://sec-api.dev/pdufa/eplontersen) (AZN)
- [ALXN2220](https://sec-api.dev/pdufa/alxn2220) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy-attr-cm.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Transthyretin Amyloid Cardiomyopathy (ATTR CM) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy-attr-cm

```bibtex
@misc{secapidev_indications_transthyretin_amyloid_cardiomyopathy_attr_cm_20261116,
  title        = {Transthyretin Amyloid Cardiomyopathy (ATTR CM) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy-attr-cm}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_transthyretin_amyloid_cardiomyopathy_attr_cm_20261116","title":"Transthyretin Amyloid Cardiomyopathy (ATTR CM) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/transthyretin-amyloid-cardiomyopathy-attr-cm","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
